Skip to main content
IMNM logo

IMNM · Immunome Inc.

Track IMNM — free
$15.69 -0.92 (-5.54%) At close · Nov 20
Market Cap
$1.85B
Shares
118.07M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.35M

Price & Indicators

 

Key stats

Close
$15.69
Fri 20 Nov
Open
$16.45
Fri 20 Nov
Average volume, 30 days
1.4M
shares a session
Short interest
16.2M
13.7% of shares · 12.8 days to cover
Day range
$15.55$16.73
Open $16.45 Close $15.69
52-week closing range
$15.69$29.83
Close $15.69 47.4% under the high
Short volume, last session
43%
Latest filing
10-Q · Nov 9
Price history
Oct 2020 to Nov 2026

Latest documents

2026
Nov 10
Investor event
Varagastat action date is end of April in 2027

Immunome expects an FDA action date at the end of April in 2027 for Varagastat while preparing a global launch. Clinical data for multiple ADCs, including IM1021, are slated for ASH, with more data expected.

6 source passages
So, obviously you have a lot going on at Immunome. there's certainly interest in varagastat in many different ways. We have an action date or PDUFA date from FDA at the end of April in 2027. We are looking at this as a global product and doing everything we can to get this to patients in need once we get approval. Okay. So maybe diving into some of those a little deeper, a question on IM1021, which is your ROAR 1 ADC. you'll hear a lot of clinical data starting with ASH, which is next month. Open the document at this passage
Nov 9
Registration statement S-3ASR
Registers $134.1 million common-stock sales agreement

Immunome registered up to approximately $134.1 million of common stock for sale through TD Securities (USA) LLC or TD Cowen, replacing a prior $200.0 million agreement under which it sold 6,655,587 shares for gross proceeds of $65.9 million.

Read from the first part of this long document
3 source passages
a sales agreement prospectus, which covers the offering, sale and issuance by us of up to a maximum aggregate offering price of approximately $134.1 million of our common stock that may be issued and sold from time to time under a sales agreement, with TD Securities (USA) LLC, or TD Cowen, as sales agent. On May 14, 2024, the Company filed a sales agreement prospectus, or the Prior Sales Agreement Prospectus, covering the offering, issuance, and sale of up to a maximum aggregate offering price of $200.0 million of shares of its common stock that could be issued and sold from time to time under a sales agreement, or the ATM Agreement, with TD Cowen. The Company had sold an aggregate of 6,655,587 shares under the ATM Agreement for gross proceeds of $65.9 million pursuant to the Prior Sales Agreement Prospectus. Open the document at this passage
Nov 9
Registration statement S-3ASR
BMS may resell 4,425,487 registered common shares

Immunome registered 4,425,487 common shares for BMS to resell after paying $20.0 million in cash for an amendment eliminating milestone and royalty obligations under its license agreement.

Read from the first part of this long document
4 source passages
Immunome, Inc. We have prepared this prospectus to allow the selling stockholder to offer and sell from time to time up to 4,425,487 shares of our common stock for its own account. As consideration for the Amendment, we paid BMS $20.0 million in cash and issued 4,425,487 shares of our common stock, or, collectively, the Amendment Consideration. On October 2, 2026, we entered into the Amendment with BMS, which removed our obligation to make any milestone and royalty payments under the License Agreement and assigned to us patent rights related to varegacestat and AL101 that were previously licensed to us under the License Agreement. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Varegacestat FDA target date set for April 28, 2027

Immunome Inc. reported positive Phase 3 RINGSIDE results for varegacestat and said the FDA accepted its NDA, assigning a PDUFA target action date of April 28, 2027. The company has generated no product-sales revenue.

Revenue $0 Net loss $85.78M Diluted EPS -$0.76
Read from the MD&A section
3 source passages
In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027. Unless otherwise indicated, all references to “Immunome,” the “Company,” “we,” “our,” “us” or similar terms refer to Immunome, Inc. and its subsidiary. We have not generated any revenues from product sales and will not be able to do so unless and until we receive regulatory approval for our product candidates. Open the document at this passage
Nov 9
Current report 8-K
Varegacestat PDUFA date set, IM-1340 IND cleared

Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026, while varegacestat’s PDUFA target action date is April 28, 2027. IM-1340 received IND clearance, with its Phase 1 trial expected to start by year-end 2026.

Financial results
3 source passages
Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026. The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027. Investigational New Drug (IND) clearance received for IM-1340, a potential first-in-class solid tumor antibody-drug conjugate (ADC), with Phase 1 trial initiation expected by year-end 2026 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$282.65M
Trailing 12 months
Revenue growth YoY
-23.2%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$212.84M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.1%
Year over year · more shares
Price change (1Y)
-10.4%
Trailing year
Short interest
13.7%
Latest settlement · 12.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −29%
below
Price vs 50-day avg −21%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −19%
trailing
YTD return −27%
this year
Relative strength −10%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $20 › 200d $22 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.70% of shares out · ▼ -6.4% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
212 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Revenue growth −23%
Y/Y
EPS growth +51%
Y/Y
Free cash flow $-200.6M
Balance sheet $653.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −47%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−29% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $20 › 200d $22 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.70% of shares out · ▼ -6.4% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
212 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16 Now $16 · 0% Range high $30
vs 200-day avg -29% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
IM-1021 9.58M the three months ended September 30, 2026 filing —
IM-1340 1.73M the three months ended September 30, 2026 filing —
IM-1617 1.63M the three months ended September 30, 2026 filing —
IM-3050 2.23M the three months ended September 30, 2026 filing —
Indirect research and development 28.5M the three months ended September 30, 2026 filing —
objective response rate (B-NHL) 53% as of the June 26, 2026 abstract data cutoff —
objective response rate (DLBCL) 64% as of the June 26, 2026 abstract data cutoff —
Other 13.27M the three months ended September 30, 2026 filing —
Total share-based compensation expense 12.76M the three months ended September 30, 2026 filing —
Varegacestat 12.58M the three months ended September 30, 2026 filing —
cash, cash equivalents and marketable securities $520M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMNM
Immunome Inc.
this stock
$1.85B -27.0% -23.2% — 13.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
212
% held
101.6%
Net QoQ
+1.9M sh
Top holder
T. Rowe Price Investment…
Held Float
View
Held by Funds
Fund positions
227
View
Short & Settlement
Short Interest Falling
Shares short
16.2M
Days to cover
12.8d
Change
-1.1M sh
View
Short Volume
Short vol %
43%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
39
Value
$679
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
40.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$6.9M
Net income (FY)
$-212.4M
EPS diluted
$-2.43
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
18

Immunome expects an FDA action date at the end of April in 2027 for Varagastat while preparing a global launch. Clinical data for multiple ADCs, including IM1021, are slated for ASH, with more data expected.

View
Proposed Sales
Value
$334.2K
Shares
13.2K
Filed
Sep 11, 2026
View
Exempt Offerings
Offering
$27.0M
Filed
May 11, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Immunome Reports Third Quarter 20…
Published
Nov 9, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IMNM -16.4% -12.8% -18.9% -13.8% -27.0%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -7.9% -3.6% -9.7% -5.1% -28.1%
Key facts CIK 1472012 CUSIP 45257U108 13F (30d) 212 filings 199 filers Visit website Investor relations